Explore updates on metastatic breast cancer research, hear from the MBC community, and learn how your support is making a difference.
METAvivor submitted a formal response to OMB-2026-0034 opposing proposed changes to federal research funding. METAvivor submitted a formal response to the Office of Management and
METAvivor signed onto a letter supporting the Clinical Trial Modernization Act. METAvivor has joined nearly 200 patient advocacy, public health, and health care organizations in
METAvivor Leads the Call for Better Cancer Registry Data As a proud Steering Committee member of the Alliance for Breast Cancer Policy, METAvivor was proud
METAvivor speaks out against proposed elimination of funding for the PCORI Trust Fund. PCORI’s patient-centered research fills a critical gap in the research landscape for
METAvivor is weighing in to make sure Congress supports America’s Cancer Registries as they set funding levels for 2027. Consistent and strong support for these
Letter from the President Kelly Shanahan, M.D. I swear these months fly by faster and faster! I hope where you live spring is firmly established,
May Advocate Monthly Update Dear METAvivor Advocates, METAvivor submitted written comments to the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) ahead of its
April Advocate Monthly Update Dear METAvivor Advocates, Both the House and Senate were in recess for much of April, but as of the 14th, both
Letter from the President Kelly Shanahan, M.D. This month I’m typing this simultaneously exhausted and energized, just back from a week of advocacy. I spent
Letter from the President Kelly Shanahan, M.D. I am writing this from an airport, a place I’ve been spending a lot of time in over
March Advocate Monthly Update Dear METAvivor Advocates, As March draws to a close, we are wrapping up our GroundSwell Virtual Advocacy event and ramping up
February Advocate Monthly Update Dear METAvivor Advocates, February has been an active month for METAvivor advocacy as we prepared for and launched our third annual
